NCT03376763

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 201 (actual)
• Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

Interventional, multicenter, open-label, 20 weeks study * To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena. * To identify efficacy and safety in switching from oral atypical antipsychotics other than aripiprazole to Abilify Maintena

Detailed description

We would like to evaluate the efficacy and safety when switching to Abilify Maintena according to the approved indication of Abilify Maintena, for subjects who are taking oral antipsychotic drugs. It is expected that this will serve as a basis for suggesting a successful switching guideline from oral antipsychotics to Abilify Maintena, which can be applicable in clinical practice.

Conditions

• Schizophrenia
• Antipsychotics
• Long-Acting Injection
• LAI
• Aripiprazole

Interventions

Type	Name	Description
DRUG	Abilify maintena	Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)

Timeline

• Start date: 2017-11-21
• Primary completion: 2021-11-19
• Completion: 2021-11-19
• First posted: 2017-12-18
• Last updated: 2021-12-17

Locations

27 sites across 1 country: South Korea